Professor of Pharmacology and Professor of Medicine
Family Medicine
Dr. Elliot Vesell, MD
|
|
Give Review
Doctor Elliot Vesell, MD practices Family Medicine. He studied medicine at Harvard Medical School. Harvard Medical School is a top medical university. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. He received awards:"Elected Member" and "Whos Who in Medicine and Healthcare". Doctor Elliot Vesell, MD is a published doctor. He has 101 papers published. The most current publication "Studies on pyrazinoylguanidine. 7. Effects of single oral doses in normal human subjects."
Publications
- Genetic risk prediction: individualized variability in susceptibility to toxicants.
- Which studies of therapy merit credence? Vitamin E and estrogen therapy as cautionary examples.
- A rational approach to the selection of useful drugs for clinical practice.
- Pharmacology and statistics: recommendations to strengthen a productive partnership.
- Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics.
- Declines in funding of NIH R01 research grants.
- The heart of drug discovery and development: rational target selection.
- The power of pharmacological sciences: the example of proton pump inhibitors.
- From progress to regression: biomedical research funding.
- Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead.
- Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements.
- Declines in NIH R01 research grant funding.
- From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions.
- Conclusions, research needs, and recommendations of the expert panel: technical workshop on human milk surveillance and research for environmental chemicals in the Uni...
- Safety issues of maternal drug therapy during breastfeeding.
- Induction of drug-metabolizing enzymes in liver microsomes of mice and rats by softwood bedding.
- Lactate dehydrogenase isozymes: further kinetic studies at high enzyme concentration.
- Sequential alterations of lactic dehydrogenase isozymes during embryonic development and in tissue culture.
- POLYMORPHISM OF HUMAN LACTATE DEHYDROGENASE ISOZYMES.
- BIOLOGICAL APPLICATIONS OF LACTIC DEHYDROGENASE ISOZYMES: CERTAIN METHODOLOGICAL CONSIDERATIONS.
- ISOZYMES OF LACTIC DEHYDROGENASE: SEQUENTIAL ALTERATIONS DURING DEVELOPMENT.
- Comparative studies of the isozymes of lactic dehydrogenase in rabbit and man. Observations during development and in tissue culture.
- Isozymes of lactice dehydrogenase; their alterations in arthritic synovial fluid and sera.
- Localization of a lactice dehydrogenase isozyme in nuclei of young cells in the erythrocyte series.
- Significance of the heterogeneity of lactic dehydrogenase activity in human tissues.
- Effect of dilution on the lactic dehydrogenase isozyme pattern obtained in the starch gel.
- Variations in the lactic dehydrogenase of vertebrate erythrocytes.
- Serum lactic dehydrogenase activity in experimental endotoxic shock.
- Plasma lactic dehydrogenase activity in experimental hemorragic shock.
- Symphalangism, strabismus and hearing loss in mother and daughter.
- Isozymes of lactic dehydrogenase in human tissues.
- Laurence-Moon-Biedl syndrome. Report of an unusual family.
- Urinary test for a metabolite of prochlorperazine.
- The heterogeneity of lactic and malic dehydrogenase.
- Observations on the heterogeneity of malic and lactic dehydrogenase in human serum and red blood cells.
- Localization of lactic acid dehydrogenase activity in serum fractions.
- Recollections from the Kunkel laboratory, 1956-1958.
- NIH budget grows, but not R01 success rates.
- The pursuit of clinical truth: role of epidemiology/observation studies.
- Advances in pharmacogenetics and pharmacogenomics.
- Studies on pyrazinoylguanidine: a novel antihypertensive, hypoglycemic and lipolytic drug intended for adjunctive use in hypertensive patients with type 2 diabetes mel...
- Are the elderly underrepresented in clinical drug trials?
- Likelihood of NIH extramural funding.
- Metabolism and disposition of 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone (NNK) in rhesus monkeys.
- Studies on pyrazinoylguanidine. 7. Effects of single oral doses in normal human subjects.
- Genetic variation as a guide to drug development.
- Pyrazinoylguanidine in end-stage renal disease: a prospective, placebo-controlled pilot study.
- Pedigree analysis of a subject with abnormally slow renal elimination of 6-hydroxychlorzoxazone.
- Studies on pyrazinoylguanidine. 6. Prevention of cataracts in STZ-diabetic rats.
- Studies on pyrazinoylguanidine. 5. Temporal effects over 24 weeks demonstrating attenuation of diabetic nephropathy in STZ-diabetic rats.
- Therapeutic lessons from pharmacogenetics.
- Acetylator phenotype in relation to age and gender in the Baltimore Longitudinal Study of Aging.
- Reflections from distant cuvettes.
- Studies on pyrazinoylguanidine. 4. Upregulation of phosphodiesterase activity in rat adipose tissue and downregulation of gluconeogenesis and adenosine 3'',5''-monopho...
- Studies on pyrazinoylguanidine. 3. Downregulation of lipolysis in isolated adipocytes.
- Studies on pyrazinoylguanidine. 2. Comparative drug and dose effects on glucose and lipid metabolism in streptozotocin-induced diabetic rats.
- Studies on pyrazinoylguanidine. 1. Characterization of metabolic effects in diabetic rats.
- Contrasting effects of pyrazinoylguanidine and hydrochlorothiazide in patients with renal insufficiency.
- Reproducibility of antipyrine half-lives in elderly subjects.
- Underrepresentation of women in clinical drug trials.
- Identification of radiolabeled metabolites of nicotine in rat bile. Synthesis of S-(-)-nicotine N-glucuronide and direct separation of nicotine-derived conjugates usin...
- Nicotine metabolism in cigarette smokers and nonsmokers.
- Effects of pyrazinoylguanidine on the glucose-fatty acid cycle in normal subjects and patients with non-insulin-dependent diabetes mellitus.
- Variables affecting nicotine metabolism.
- Rates of excretion of cotinine, nicotine glucuronide, and 3-hydroxycotinine glucuronide in rat bile.
- Women in clinical drug trials. An update.
- Studies on interindividual variations of CYP2E1 using chlorzoxazone as an in vivo probe.
- Limitations of probit plots in pharmacogenetics: requirement of genetic analyses to test hypotheses based on graphical methods.
- Pyrazinoylguanidine downregulates the glucose fatty-acid cycle in hypertensive, hyperinsulinemic diabetic patients.
- Basal and paracetamol-depleted glutathione from human lymphocytes: ethnic variability.
- Clinical pharmacology: a new specialty.
- Inhibition of theophylline metabolism by long-term allopurinol administration.
- The influence of host factors on drug response. IV. Occupation.
- The influence of host factors on drug response. III. Diet.
- Antipyrine metabolism during the menstrual cycle.
- The influence of host factors on drug response. II, Age.
- Training programs in clinical pharmacology.
- Further observations on relationships between antipyrine half-life, clearance and volume of distribution: an appraisal of alternative kinetic parameters used to assess...
- Elucidation of the pharmacokinetic interaction between acutely administered ethanol and benzodiazepines.
- The influence of host factors on drug response. VI. Hepatocellular diseases.
- The influence of host factors on drug response. V. Endocrinological, gastrointestinal, and pulmonary diseases.
- The influence of host factors on drug response. VII. Renal diseases.
- The influence of host factors on drug response. VII. Implications for interpretation of clinical trials and other published studies on drug response in man.
- Antipyrine and warfarin disposition in a patient with idiopathic hypoalbuminemia.
- Underrepresentation of women in new drug trials.
- Hydrochlorothiazide-induced 131I excretion facilitated by salt and water.
- Further studies on the increase in drug-metabolizing capacity adjacent to intrahepatic Morris hepatomas.
- Dietary patterns and diurnal variations in aminopyrine disposition.
- Genetic and environmental factors affecting the metabolism of carcinogens.
- Smoking-induced changes in nicotine disposition: application of a new HPLC assay for nicotine and its metabolites.
- Crisis in NIH funding.
- Antipyrine disposition in milk and saliva of lactating women.
- Sex differences in absorption kinetics of sodium salicylate.
- On the significance of host factors that affect drug disposition.
- Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins.
- Basic requirements for in vitro metabolic activation systems in mutagenesis testing.
- Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation.
- Influence of different forms of tobacco intake on nicotine elimination in man.
- Time-dependent induction of hepatic drug metabolism in rats by cotinine.
- Sounding board. Why are toxic reactions to drugs so often undetected initially?
Schools
Harvard Medical School
Doctors Specialties
- Clinical Pharmacology
- Family Medicine
Accepted Insurances
Awards
- Elected Member
- Whos Who in Medicine and Healthcare
Education
-
National Institutes of Health Clinical Center -
Brigham and Women's Hospital -
Massachusetts General Hospital -
Harvard Medical School
Helpful Reviews
Similar Doctors
|
|
Dr. Sourav Das, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicolas Bustamante, MD |
|
|
Dr. Charis James, MD |
|
|
Dr. Roger A. Heim, DO |
|
|
Dr. Gerard D. Kaiser Sr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amina Zubair, MD |
|
|
Dr. Frank J. Battista, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Linda L. Chambers, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sudeep J. Ross, MD |